Trastuzumab emtansine (Kadcyla®)

Assessment Status Assessment process complete
Drug Trastuzumab emtansine
Brand Kadcyla®
Indication For the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.
Assessment Process
Rapid review commissioned 25/09/2013
Rapid review completed 24/10/2013
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Full pharmacoeconomic assessment commissioned by HSE 05/02/2014
NCPE assessment completed 30/06/2014
NCPE assessment outcome Reimbursement Not Recommended.

The NCPE do not recommend reimbursement of trastuzumab emtansine (Kadcyla®) at the submitted price.

Technical Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.